Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, these findings elucidate the adaptive advantage provided by KEAP1/NRF2 pathway activation in KL tumors and support clinical testing of glutaminase inhibitor in subsets of KRAS-mutant lung adenocarcinoma.
|
31040157 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of current studies, we suggest that the rational combination of Nrf2 suppression with chemical agents which cause enhanced oxidative imbalance or abnormal metabolism would be promising in the treatment of lung adenocarcinoma.
|
30556750 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also did a brief analysis of The Cancer Genome Atlas (TCGA) data of lung adenocarcinoma concerning the effects of radiation therapy and found that the therapy-induced Nrf2 activation is not universal.
|
31717324 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Second, gene expression-based subtyping revealed three molecular subsets of KEAP1/NRF2-mutant lung adenocarcinomas and two molecular subsets of KEAP1/NRF2-mutant lung squamous cell carcinomas, each associated with distinguishing genetic, differentiation, immunological and clinicopathological properties.
|
30411339 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we discovered the gene signature associated with <i>KEAP1</i> mutations, prognostic genes which were highly correlated with the upregulation of the NRF2 pathway in the KEAP1 mutated LUAD patients.
|
31839815 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, the lung adenocarcinoma cell line A549 with constitutively expressed Nrf2 was found to be more tolerant to H<sub>2</sub>O<sub>2</sub> (0.1, 0.2, 0.5 and 1 mM) than normal lung cell line L132 or p53 null lung cancer cell line H1299.
|
29486183 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the KEAP1/NRF2 pathway have been identified in 23% of lung adenocarcinomas, suggesting that deregulation of the pathway is a major cancer driver.
|
29526543 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene.
|
30333878 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma.
|
28604754 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Nrf2 enhances the anticancer effect of 6-O-angeloylenolin in lung adenocarcinoma.
|
28104435 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice.
|
28967920 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma.
|
26923328 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
ROS/Autophagy/Nrf2 Pathway Mediated Low-Dose Radiation Induced Radio-Resistance in Human Lung Adenocarcinoma A549 Cell.
|
26078725 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the Nrf2 protein levels and antiapoptotic and antioxidant enzyme levels are higher in lung adenocarcinoma than in normal tissues.
|
26385919 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SNP (-617C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women.
|
24040073 |
2013 |